Company newsBIIB
Explain this story: Biogen reports 52-week litifilimab data for lupus treatment
Biogen (NASDAQ:BIIB) has announced 52-week results from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE). The data showed improvements in skin disease activity, with 27.2% of initial participants achieving clear or almost clear skin by week 52, and 33.7% of those who switched from placebo to litifilimab also showing significant improvement. The drug was generally well-tolerated, and the Phase 3 study results are anticipated in the first half of 2027, as there are currently no approved targeted therapies for CLE.
OtherInvesting.com IndiaSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Biogen (NASDAQ:BIIB) has announced 52-week results from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE). The data showed improvements in skin disease activity, with 27.2% of initial participants achieving clear or almost clear skin by week 52, and 33.7% of those who switched from placebo to litifilimab also showing significant improvement. The drug was generally well-tolerated, and the Phase 3 study results are anticipated in the first half of 2027, as there are currently no approved targeted therapies for CLE.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Oct 2, 2026, 11:29 ET · on this site +1h 2m